Clinical Trial

Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence

Study acronym: SUPERB
Recruiting
View on ClinicalTrials.gov →
Summary
Recently, the Radiation Oncology Department at Fondazione IRCCS San Gerardo dei Tintori has been renovated and has been equipped with cutting edge technologies to treat prostate cancer. Specifically, the now available technology can track organ motion in real time, thus allowing improved precision in radiation delivery, with increased protection of the surrounding organs at risk. These facilities have already enabled the kickoff of two prospective observational trials, the ABRUPT and the POPART, which are currently ongoing in the treatment of intact prostate and the biochemical recurrence, respectively. Taken together, these observations provide the basis for the prospective clinical study herein proposed. Patients enrolled in the study will undergo salvage single stereotactic RT to the prostate bed by means of image guided volumetric intensity-modulated arc technique (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures, with emphasis on normal tissue sparing and and pinpoint delivery accuracy via the use of devices that ensure stability and beam location reproducibility
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2026-01-29.
Trial Details
NCT Number NCT06941363
Lead Sponsor University of Milano Bicocca
Conditions Prostate Cancer (Post Prostatectomy)
Enrollment 50 participants
Start Date 2025-05-02
Primary Completion 2033-05 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-02